Lemtrada is an intravenous medication used to treat multiple sclerosis. Since it was approved, patients have been suffering from strokes and arterial dissection. Adverse events prompted the FDA to issue a Drug Safety Communication warning of risk of strokes and tears in lining of arteries of the head and neck in MS patients who are administered Lemtrada, mandating a boxed warning, the most serious type of label warning.
If you’ve taken Lemtrada and have experienced an ischemic stroke, hemorrhagic stroke, or head or neck (cervicocephalic) arterial dissection, the drug company may be liable for your injury. Fill out the form below, and an attorney will assess your case.